2017 American Transplant Congress
Generation of Natural Antibodies Post Transplant and Association with Kidney Allograft Loss.
The development of donor specific antibodies (DSA) reacting to mismatched donor class I and class II HLA is a prominent risk factor for kidney graft…2017 American Transplant Congress
Development of De Novo Donor Specific Antibodies (dnDSAs) Not the Presence of Pre-Transplant Donor Specific Antibodies (Pre-DSAs) Increase Rejection Risk in Crossmatch Negative Kidney Transplant Recipients.
Mayo Clinic Arizona, Phoenix, AZ
Aim: Study the impact of Pre-DSAs on allograft outcomes in crossmatch negative kidney transplant recipients.Methods: Single center retrospective analysis of characteristics and outcomes of kidney…2017 American Transplant Congress
Low Level Early Onset De Novo DSA's May Not Portend Early Graft Dysfunction in Kidney Transplant Recipients.
Nephrology and Hypertension, Stony Brook Medicine, Stony Brook, NY
Background: The occurrence of anti-HLA de novo DSA (dnDSA) has been associated with the histological features of antibody-mediated rejection (ABMR) on kidney biopsy. The significance…2017 American Transplant Congress
Hypogammaglobulinemia in Pediatric Heart Transplant Candidates Is Not Corrected by Transplantation.
Introduction: Hypogammaglobulinemia (HG) is associated with poor outcomes in adult heart transplant recipients but is not well studied in pediatric recipients. We therefore investigated longitudinal…2016 American Transplant Congress
Cross-Talk Between TLR and BCR Pathways Induces CNI-Resistance in B-Cells Responding to Blood Group A-Antigens: A Novel Paradigm for Treatment with TLR-Inhibitor for CNI-Resistant AMR.
Hiroshima University, Hiroshima, Japan.
[Aim] Bacterial infections after ABO-incompatible transplantation are associated with refractory antibody (Ab)-mediated rejection (AMR). We demonstrated that bacterial pathogens provoke B cells, responding to human…2016 American Transplant Congress
Treatment for AMR and DSA: A Center Based Review of Pediatric Orthotopic Heart Transplant Recipients.
PURPOSE: The aim of this study was to retrospectively analyze the clinical course of pediatric orthotopic heart transplant patients diagnosed with antibody mediated rejection (AMR+)…2016 American Transplant Congress
Impact of Angiotensin II Type I Receptor Antibody Positivity in Highly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
Introduction: Angiotensin II type I receptor antibody (AT1R Ab) is a target for non-HLA antibodies. AT1R ab exert direct effects on endothelial and vascular smooth…2016 American Transplant Congress
Anti-Angiotensin II Type 1 Receptor Antibody Reduction with Proteasome Inhibitor-Based Desensitization.
University of Cincinnati, Cincinnati.
Background. Desensitization results have largely focused on effects on anti-HLA antibody (HLA-Ab) and anti-ABO antibody levels. Anti-angiotensin II type 1 receptor antibody (AT1R-Ab) has recently…2016 American Transplant Congress
Interaction Between Kidney Tissue Proteome and Humoral Immunity in Antibody Mediated Rejection.
PURPOSE: Antibody-mediated rejection (AMR) is caused by antibodies against human leukocyte antigens (HLA) on graft endothelium, and non-HLA antibodies that target endothelial and epithelial proteins.…2016 American Transplant Congress
Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein I Is a Predictive Marker for Graft Loss in Patients Positive for IgA aB2GPI.
Immunology, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain.
Pretransplant IgA anti Beta-2-Glycoprotein 1 antibodies (IgA aB2GPI) is a risk marker for early kidney graft lost, mainly by thrombosis. About 30% of patients are…
- « Previous Page
- 1
- …
- 41
- 42
- 43
- 44
- 45
- …
- 57
- Next Page »